CXCL8 and non-small cell lung carcinoma: Moreover, various clinical trials of combining the anti-PD1 antibody, nivolumab, and CXCL8 antibodies have also been carried out in both advanced solid tumors (NCT03184870), hepatocellular carcinoma (NCT04050462), and NSCLC (NCT0413379).